A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.
暂无分享,去创建一个
B. Mellado | B. Somer | M. Stöckle | C. Reuter | I. Durán | D. Castellano | S. Wedel | S. Callies | P. Wiechno | P. Chłosta | M. Lahn | J. Kamradt | B. Heinrich | J. Pikiel | V. André | José Manuel Cervera Grau | K. Hurt | Jacqueline M Brown | Jacqueline Brown